Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) — The “Epigenetics Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering.
Global Epigenetics Diagnostics Market has valued at USD 12.25 Billion in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 7.25% through 2028. In the ever-evolving landscape of healthcare, one of the most promising and innovative fields gaining prominence is epigenetics diagnostics. Epigenetics, the study of changes in gene expression or cellular phenotype without alterations to the underlying DNA sequence, has revolutionized our understanding of various diseases and their potential diagnostics and treatments. The Global Epigenetics Diagnostics Market is at the forefront of this transformation, offering new avenues for personalized medicine and disease management. Epigenetic modifications involve chemical alterations to DNA and histone proteins, which can influence gene activity. These modifications can be heritable and are influenced by environmental factors, making epigenetics a dynamic field for exploring the relationship between genetics and health.
The global burden of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders is on the rise. Epigenetics diagnostics offer insights into disease susceptibility and progression, allowing for early detection and personalized treatment strategies. Advances in high-throughput sequencing, DNA methylation analysis, and histone modification profiling have made epigenetics diagnostics more accessible and cost-effective, accelerating market growth. The shift towards precision medicine emphasizes tailoring treatments to an individual’s unique genetic and epigenetic profile. Epigenetics diagnostics play a crucial role in identifying suitable treatment options. As the global population continues to age, the demand for diagnostic tools that can predict and monitor age-related diseases is increasing. Epigenetics provides valuable insights into age-related changes in gene expression.
Key Market Drivers
- Increasing Incidence of Complex Diseases is Driving the Global Epigenetics Diagnostics Market
- Increasing Pharmaceutical Research and Drug Development is Driving the Global Epigenetics Diagnostics Market
Key Market Challenges
- Complexity of Epigenetic Modifications
- Lack of Standardization
- Data Interpretation and Analysis
- Biomarker Discovery
- Ethical and Regulatory Issues
- Cost and Accessibility
- Integration into Clinical Practice
Report Scope:
In this report, the Global Epigenetics Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Epigenetics Diagnostics Market, By Product:
- Reagents
- Kits
- Instruments
- Enzymes
- Services
Epigenetics Diagnostics Market, By Application:
Epigenetics Diagnostics Market, By Technology:
- DNA Methylation
- Histone Methylation
- Histone Acetylation Large noncoding RNA
- MicroRNA modification
A selection of companies mentioned in this report includes
- Roche Diagnostics
- Thermo Fisher Scientific, Inc.
- Eisai Co. Ltd.
- Novartis AG
- Element Biosciences, Inc.
- Dovetail Genomics LLC.
- Illumina, Inc.
- ValiRx Plc.
- Abcam plc
For more information about this report visit https://www.researchandmarkets.com/r/7raokc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Epigenetics Diagnostics Market
